Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) shares rose 3.4% during mid-day trading on Thursday . The company traded as high as $0.98 and last traded at $0.97. Approximately 37,468 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 1,047,134 shares. The stock had previously closed at $0.94.
Analyst Ratings Changes
CTOR has been the topic of several recent research reports. Citigroup lowered Citius Oncology to a "hold" rating in a research report on Friday, May 23rd. Maxim Group cut shares of Citius Oncology from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd.
Read Our Latest Stock Report on Citius Oncology
Citius Oncology Stock Up 17.1%
The firm's 50-day simple moving average is $0.81 and its 200-day simple moving average is $0.98. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.08 and a current ratio of 0.34.
Citius Oncology (NASDAQ:CTOR - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02).
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Citius Oncology stock. IFP Advisors Inc boosted its position in Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) by 173.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 22,215 shares of the company's stock after acquiring an additional 14,080 shares during the period. IFP Advisors Inc's holdings in Citius Oncology were worth $26,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 70.52% of the company's stock.
Citius Oncology Company Profile
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Featured Articles
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
